Neuren receives $0.9m from exercise of last expiring options
Filed with ASX · · 1 page · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren expands Phase 2 Rett syndrome pediatric trial
- Neuren presents at Rettsyndrome.org 2016 Research Symposium
- Grant of new patent for Autism Spectrum Disorders
- Results of Phase 2 trial in moderate to severe TBI
- First subject commences Neurens Rett syndrome Phase 2 trial
Later from Neuren Pharmaceuticals
- Neuren completes enrolment in Rett syndrome Phase 2 trial
- Notice of special meeting of shareholders
- Neuren completes Phase 2 trial in pediatric Rett syndrome
- Trofinetide significant clinical benefit in Rett syndrome
- Neuren receives $1 million R&D Tax Incentive
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals